Plerixafor Injection, Solution
NDC 65219-284
Product Information
Plerixafor is a NDA AUTHORIZED GENERIC-approved product labeled by Fresenius Kabi Usa, Llc. Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. It is supplied as a injection, solution for subcutaneous administration. This product entry covers the primary NDC 65219-284 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 65219-284?
What are the uses of this product?
What are Active Ingredients of this product?
- PLERIXAFOR 24 mg/1.2mL - a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PLERIXAFOR (UNII: S915P5499N)
- PLERIXAFOR (UNII: S915P5499N) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- WATER (UNII: 059QF0KO0R)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 828700 - plerixafor 24 MG in 1.2 ML Injection
- RxCUI: 828700 - 1.2 ML plerixafor 20 MG/ML Injection
- RxCUI: 828700 - plerixafor 24 MG per 1.2 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Plerixafor Injection
Plerixafor injection is used along with a granulocyte-colony stimulating factor (G-CSF) medication such as filgrastim (Neupogen) or pegfilgrastim (Neulasta) to prepare the blood for an autologous stem cell transplant (procedure in which certain blood cells are removed from the body and then returned to the body after chemotherapy and/or radiation) in patients with non-Hodgkin's lymphoma (NHL; cancer that begins in a type of white blood cells that normally fights infection) or multiple myeloma (a type of cancer of the bone marrow). Plerixafor injection is in a class of medications called hematopoeitic stem cell mobilizers. It works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplant.
[Learn More]
* Please review the full disclaimer at the bottom of this page.